Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358721 · ClinicalTrials.gov registry record · Phase 1
Phase I Biomarker Study (BMS-936558)
A Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
- 14
- Study locations
NCT01358721 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 119 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (51% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT01358721, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
Conditions Studied
Interventions
- DRUG BMS-936558 (Anti-PD-1)
Study Locations (14)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana Farber Cancer Inst - Boston
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Upmc Cancer Pavilion - Pittsburgh
Other
- Local Institution - Villejuif
- Local Institution - Pamplona
California
- Ucsf Helen Diller Family Comprehensive Cancer Center - San Francisco
Connecticut
- Yale University School Of Medicine - New Haven
Florida
- H. Lee Moffitt Cancer Center - Tampa
Illinois
- University Of Chicago Medical Center - Chicago
Maryland
- The Bunting-Blaustein Cancer Research Building - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2011-09-23 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358721
The ClinicalTrials.gov registry entry for NCT01358721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (51% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which BMS-936558 (Anti-PD-1) is the first listed.
NCT01358721 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT01358721 about?
NCT01358721 is a clinical study titled "Phase I Biomarker Study (BMS-936558)". The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
What is the current status of trial NCT01358721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2011-09-23. Estimated completion is 2019-05-22.
What conditions does trial NCT01358721 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT01358721?
The interventions under investigation include: BMS-936558 (Anti-PD-1) (DRUG).
Who is sponsoring clinical trial NCT01358721?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358721 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.